ORIGINAL
RESEARCH

Family Medicine and Community Health
ORIGINAL RESEARCH

Use of prostate-specific antigen testing in Medicare beneficiaries:
Association with previous evaluation
Gregory S. Cooper1,3, Tzuyung Doug Kou1, Mark D. Schluchter3,4, Avi Dor5, Siran M. Koroukian3,4, Simon P. Kim2,3

Abstract
Objective: Determine uptake of prostate-specific antigen (PSA) testing in Medicare beneficiaries according to previous receipt of PSA testing.
Methods: A 5% random sample of men aged 67 years or older without a previous diagnosis of
prostate cancer was identified through 2009–2012 Medicare claims. We measured the annualized
frequency of PSA screening among men due for PSA testing, stratified by PSA testing use in the
previous 2 years, and clustered by ordering provider.
Results: Throughout the study period, PSA testing use was consistently higher for men with
previous screening than for men without previous screening. For men without previous screening,
there was a decline in testing that was most pronounced in 2012. Compared with 2009, the corresponding odds ratios were 0.98 [95% confidence interval (CI) (0.96–1.00)] in 2010, 0.94 [95%
CI (0.92–0.95)] in 2011, and 0.66 [95% CI (0.65–0.68)] in 2012. In contrast, for men with previous
screening, PSA testing frequency was stable from 2009 to 2011, and declined to a lesser extent in
2012 [odds ratio 0.80, 95% CI (0.79–0.81)].
Conclusion: Receipt of PSA testing is highly dependent on whether an individual was tested
in the recent past. In previously unscreened men, the largest decrease occurred in 2012, which may
reflect in part the publication of US Preventive Services Task Force guidelines, but there was much
less impact among men already being screened.
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Introduction

routine prostate cancer screening with either

Prostate cancer is among the most frequently

PSA testing or digital rectal examination

diagnosed cancers in the United States, both

in men younger than 75 years [2]. In con-

overall and in the Medicare-eligible popula-

trast, it concluded that the potential harms

tion (aged 65 years or older) [1]. Despite the

of screening would outweigh the benefits in

high incidence and mortality associated with

men aged 75 years or older. In May 2012, the

prostate cancer [1], the merits of prostate-spe-

revised USPSTF guidelines recommended

cific antigen (PSA) screening in the general

that prostate cancer screening no longer be

population are controversial. In 2008, the US

performed by either method in men who

Preventive Services Task Force (USPSTF) ini-

are of average risk of having prostate cancer

tially determined that there was insufficient

[3]. Other guidelines, including those of the

evidence to recommend or not recommend

American Cancer Society [4], the American
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Urological Association [5], and most recently, the National

were contained in the sample from year to year. To measure

Comprehensive Cancer Network [6] recommended that men

the use of PSA testing, we included files from 2009 to 2012,

who are aged 50–74 years, 55–69 years, and 45–75 years

with the 2004–2008 data used to exclude previous prostate

respectively and have at least a 10-year life expectancy should

cancer diagnoses and determine previous use of PSA testing.

have an opportunity to make an informed decision with their

The relevant files included the Medicare Carrier Files, the

health care provider about whether to be screened for pros-

Medicare Outpatient Files, and the Medicare Beneficiary

tate cancer. In addition, the American Urological Association

Summary Files.

guidelines recommend every other year testing among men
who elect to have PSA screening [5].

In addition, we used the 2010 US Census data, which provided ZIP-code level information of socioeconomic status.

Previous studies have used administrative data, including

These data were used as ecological measures in the patient-

Medicare claims and Veterans Administration files, to exam-

level regression analyses. The 2010 American Medical

ine the use of PSA testing according to age and publication of

Association Masterfile, which contains information on both

practice guidelines and clinical trial data [7–12]. Studies have

American Medical Association members and nonmembers,

documented variability in the use of screening according to

was used to categorize physician density per 100,000 popula-

geographic region [12] and physician characteristics [11], as

tion at the county level.

well as a modest decline in screening following the publica-

The sample was limited to men aged 67 years or older

tion of the 2008 [8, 11, 13] and 2012 [14–17] USPSTF guide-

who were contained in the 5% random sample of Medicare

lines [2,3] and screening trial publications [18, 19]. Three

beneficiaries and continuously enrolled. Because Medicare

recently published studies used data from the National Health

enrollment typically begins at age 65 years, this age restric-

Interview Survey [20–22] and reported declines in PSA test-

tion was used so as to have at least a 2-year look-back period

ing use following publication of the USPSTF guidelines.

to exclude men with a previous diagnosis of prostate cancer

However, despite the consensus that if PSA testing is offered,

or prostate carcinoma in situ [International Classification of

it should be performed on a regular (i.e., annual or biannual)

Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)

basis, all studies have used a cross-sectional approach to meas-

185, 233.4, 602.3, V10.46], which have different guidelines, as

ure screening. In these studies, PSA testing was considered as

well as to measure PSA testing use in the preceding 2 years.

a one-time event and patients were not stratified according to

Also, because of the high likelihood of incomplete claims,

previous use of screening or whether they were up to date with

we excluded beneficiaries who were enrolled in Medicare-

screening.

managed care plans during the look-back period as well as

We therefore performed a population-based analysis with

those who were not enrolled in Medicare Part A and Part B.

Medicare claims data to determine the use of PSA testing

To limit the analysis to PSA testing performed for probable

according to receipt of previous screening. In addition to meas-

screening indications as opposed to surveillance or symptom

ures of previous PSA testing, our analyses also considered fac-

evaluation, we used a previously developed and validated algo-

tors such as sociodemographics, comorbidity, and physician

rithm to increase the specificity of PSA testing [6]. In addition

supply. We hypothesized that the frequency of screening did

to a prostate cancer diagnosis, this algorithm also excluded

not change among men who were already undergoing testing

men with a history of prostatectomy, androgen deprivation

but declined in men who were previously not screened.

therapy, or elevated PSA level, and also urinary symptoms
within 3 months before the PSA test claim.

Methods
Data sources

Measures

The study cohort included claims from a 5% random sample

Demographic characteristics were obtained from Medicare

of Medicare beneficiaries from 2004 to 2012. On the basis of

claims, and included age and race. Ecological measures of

the selection criteria for the 5% sample, the same beneficiaries

socioeconomic status included median household income
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and proportion of high school graduates among adults aged

previous 2-year period, or whether the patient had undergone

25 years or older. A previously validated, weighted comorbid-

testing during the previous 2 years and was due for repeated

ity index that included both outpatient and inpatient diagnosis

screening.

codes was included for the 12-month to 1-month period before

Univariate analysis was used to determine the association

the PSA test date or the end of the follow-up period [23]. As

of calendar year with the use of PSA testing. Because indi-

previously defined, to exclude “rule out” diagnoses, a comor-

vidual patients were eligible for screening in more than 1 year,

bid condition had to appear more than once in outpatient files.

generalized estimating equation (GEE) logistic regression was

The Beneficiary Summary File contained fields for state buy-

used to account for within-patient correlation. In addition, as

in and dual eligibility, which indicate lower socioeconomic

individual providers tend to have unique practice patterns with

status and/or with heightened vulnerability. The geographic

regard to PSA testing, we included physician clustering in the

region of residence was divided into Northeast, Midwest,

GEE regression models. We then used multivariate GEE mod-

South, and West.

els to determine the independent association of demographic,

During each calendar month, we considered the propor-

socioeconomic and clinical measures with receipt of PSA test-

tion of eligible men who received one or more PSA tests,

ing. As in the monthly frequencies, the analyses were stratified

divided by the number of men who were otherwise eligible

according to the presence of previous PSA testing. For men

for screening and who had not received a PSA test during

with previous PSA testing, we also added a covariate for the

the previous 24 months. Men were included in the numera-

time since the most recent PSA test.

tor only if they actually received a PSA test during that

The Medicare claims data were obtained through a data

month, and the denominator changed from month to month

use agreement with the Centers for Medicare and Medicaid

as new men became due for testing. PSA tests were identi-

Services, and approval was obtained from the University

fied through relevant procedure codes (CPT-4 84153, G0103).

Hospitals Cleveland Medical Center Institutional Review

To account for delays in obtaining screening, a 90-day exten-

Board.

sion from the beneficiary’s due date for repeated screening
was used to satisfy the criterion for screening. This approach

Results

was previously used in a study of the impact of health care

Using the 5% random sample of Medicare beneficiaries

reform on receipt of mammography and colonoscopy [24].

in 2009–2012, we identified 1,614,857 eligible beneficiar-

Beneficiaries were censored at the month of death or disen-

ies. From this cohort, we excluded 1,201,421 for the follow-

rollment from fee-for-service Medicare plans on the basis of

ing non-mutually exclusive indications: age younger than 70

the Beneficiary Summary File. We also censored individuals

years (n=696,971), enrollment in Medicare-managed care

at the time of prostate cancer diagnosis (ICD-9-CM 185) dur-

plans (n=442,615), lack of enrollment in Medicare Part B

ing 2009–2012.

(n=435,579), prior prostate cancer diagnosis (n=5871), and
enrollment because of end-stage renal disease or disability

Analysis

(n=23,188). The final sample consisted of 598,184 men, includ-

We first summarized PSA testing frequency by calendar

ing 333,514 (55.8%) with at least one PSA test and 264,670

month according to whether the patient was due for screen-

(44.2%) with no evidence of PSA testing.

ing during that month (i.e., no PSA test in the previous 24

The characteristics of men with and without PSA test-

months). Because of the 90-day window to account for being

ing are shown in Table 1. The age distribution of the group

up to date with testing, a cutoff for the due date of September

with PSA testing was somewhat in favor of older age com-

30, 2012, was used, and patients with due dates after that were

pared with the group without PSA testing, whereas the

excluded for calculation of frequencies for October through

racial and ethnic distribution was similar between the two

December 2012. The analyses were stratified according to

groups. The PSA group had a higher proportion of men with

whether the patient had no evidence of PSA testing during the

at least one comorbid condition. Men with PSA testing were
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Table 1. Demographic characteristics of men according to prostate-specific antigen testing

Total
Mean age at cohort entry±SD (years)
Age at cohort entry (years)
67–69
70–74
75–79
80+
Ethnicity
White
African American
Other/unknown
Hispanic
Comorbidity score
0
1
2
3+
Geographic region
Northeast
Midwest
South
West
Income quartile
1 (lowest)
2
3
4 (highest)
Education quartile
1 (lowest)
2
3
4 (highest)
Primary care physician density
1 (lowest)
2
3
4 (highest)
Urologist density
1 (lowest)
2
3
4 (highest)
State buy-in
No
Yes

Without PSA testing

With PSA testing

264,670
76.1±7.9

333,514
76.1±6.5

117,475 (44.4%)
48,484 (18.3%)
37,737 (14.3%)
60,974 (23.0%)

121,287 (36.4%)
79,596 (23.8%)
60,101 (18.0%)
72,530 (21.8%)

225,940 (85.3%)
22,184 (8.4%)
16,546 (6.3%)
4975 (1.9%)

287,233 (86.1%)
24,869 (7.5%)
21,412 (6.4%)
6437 (1.9%)

142,188 (53.7%)
45,405 (17.2%)
25,328 (9.5%)
51,749 (19.6%)

126,235 (37.9%)
80,543 (24.1%)
43,309 (13.0%)
83,427 (25.0%)

29,117 (11.0%)
80,564 (30.4%)
93,648 (35.4%)
61,341 (23.2%)

32,785 (9.8%)
73,265 (22.0%)
160,981 (48.3%)
66,483 (19.9%)

P

<0.0001

<0.0001

<0.0001

<0.0001

<0.0001
71,708 (27.1%)
73,961 (27.9%)
65,703 (24.9%)
53,298 (20.1%)

80,999 (24.3%)
81,652 (24.4%)
84,284 (25.3%)
86,579 (26.0%)

73,772 (27.9%)
71,656 (27.1%)
64,036 (24.1%)
55,206 (20.9%)

78,910 (23.7%)
79,577 (23.8%)
84,386 (25.3%)
90,641 (27.2%)

65,696 (24.8%)
67,782 (25.6%)
64,513 (24.4%)
66,679 (25.2%)

72,196 (21.7%)
74,952 (22.5%)
85,335 (25.6%)
101,031 (30.3%)

67,707 (25.6%)
72,159 (27.2%)
66,409 (25.1%)
58,395 (22.1%)

70,576 (21.2%)
81,485 (24.4%)
86,244 (25.8%)
95,209 (28.6%)

234,358 (88.5%)
30,312 (11.5%)

298,652 (89.5%)
34,862 (10.5%)

<0.0001

<0.0001

<0.0001

<0.0001

PSA, prostate-specific antigen; SD, standard deviation.
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more likely to live in the South and reside in regions with

2009

2010

2011

2012

5

a higher median income and educational level as well as in
regions with a greater density of primary care providers and

4.5

The monthly frequencies of PSA testing according to
receipt of previous screening are shown in Fig. 1. Within a
given month, the screening rates were consistently higher for
men with previous screening (typically 13%–16% of those due
for screening) than for men without testing in the previous 2
years (typically 3%–4%). For men without previous screen-

Screened (%)

urologists.
4
3.5
3
2.5

ing, there was a decline in the frequency of testing according to calendar year, and this was most pronounced in 2012

2

0

1

(Fig. 2). Compared with 2009, the corresponding odds ratios
were 0.98 [95% confidence interval (CI) 0.96–1.00] in 2010,
0.94 (95% CI 0.92–0.95) in 2011, and 0.66 (95% CI 0.65–0.68)
in 2012. In contrast for men with previous screening, the test-

2

3

4

5

6

7

8

9

10

11

12

Month

Fig. 2. Monthly rates of prostate-specific antigen testing in men
without previous testing. The rates declined in each year of the
analysis.

ing frequencies were relatively constant from 2009 to 2011,
and declined more modestly in 2012. The corresponding odds
ratios were 0.98 (95% CI 0.97–0.99) in 2010, 0.99 (95% CI
0.98–1.00) in 2011, and 0.80 (95% CI 0.79–0.81) in 2012. In
addition, for both groups and all study years, use of PSA testing tended to be higher in the earlier part of the calendar year
than in the later part.
The results of the multivariate GEE analyses for men
with previous PSA testing are shown in Table 2. PSA testing was less common in African Americans and men in the
2009

18

2010

2011

northeastern United States. There was minimal or no association of median income or density of primary care physicians, but screening tended to be more frequent in regions
with higher median educational levels. However, PSA testing
use was highest in regions with a greater density of urologists.
There was no substantive association of calendar year through
2011 with PSA testing use, but use did decline in 2012.
In contrast, the multivariate results of PSA testing among
men without previous screening differed across many parameters (Table 3). In this group, there was a pronounced decline

2012

with older ages, but an increase in PSA testing use with higher
levels of comorbidity. African Americans were less likely but

Screened (%)

17

members of other racial groups were more likely to be tested.
The highest use of testing was found in the southern United

16

States, and PSA testing use tended to be highest in regions
with higher median income and educational level. In contrast

15

to men with previous screening, there was no consistent asso-

14

ciation with urologist density. Also, in contrast to the previously screened men, the frequency of PSA testing declined

13

over time in men without recent screening, especially for 2012.
12

0

1

2

3

4

5

6
7
Month

8

9

10

11

12

Discussion

Fig. 1. Monthly rates of prostate-specific antigen testing in men with

Although prostate carcinoma is commonly diagnosed and is

previous testing. The rates remained fairly constant until 2012, when

a leading cause of cancer-related death among men, the ben-

they declined.

efits and harms of PSA screening for this cancer in the general
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Table 2. Multivariate analysis of prostate-specific antigen testing

Table 2 (continued)

among men with previous prostate-specific antigen testing and due
for repeated testing

Adjusted
Adjusted

95% Confidence

OR

Age group (years)
67–69
70–74
75–79
80+
Race
White
African American
Other
Comorbidity score
0
1
2
3+
Geographic region
Northeast
Midwest
South
West
Income quartile
1 (lowest)
2
3
4 (highest)
Education quartile
1 (lowest)
2
3
4 (highest)
Primary care
physician density
1 (lowest)
2
3
4 (highest)
Urologist density
1 (lowest)
2
3
4 (highest)

Referent
1.04
0.99
0.76

P

limits
Lower

1.02
0.97
0.75

Upper

1.05
1.00
0.77

<0.0001
0.0376
<0.0001

Referent
0.92
1.05

0.90
1.03

0.94
1.08

<0.0001
<0.0001

Referent
1.06
1.04
0.95

1.05
1.03
0.94

1.07
1.06
0.96

0.0844
0.0643
0.6796

Referent
0.78
0.93
0.86

95% Confidence

OR

P

limits
Lower

Upper

Calendar year
2009
2010
2011
2012
Time since last PSA

Referent
0.98
0.99
0.80
1.002

0.97
0.98
0.79
1.002

0.99
1.00
0.81
1.002

<0.0001
0.0175
<0.0001
<0.0001

test (years)
State buy-in
No
Yes

Referent
0.95

0.93

0.97

<0.0001

OR, odds ratio; PSA, prostate-specific antigen.

population are controversial. Consequently, given the concerns
about false positive tests, overdiagnosis, and overtreatment,
none of the current practice guidelines recommend universal
screening [3–6]. Our study, which used a longitudinal design

0.77
0.91
0.84

0.80
0.95
0.88

<0.0001
<0.0001
<0.0001

0.98
0.98
0.98
Referent

0.96
0.96
0.97

1.00
1.00
1.00

0.0560
0.0203
0.0164

0.88
0.90
0.96
Referent

0.86
0.88
0.95

as opposed to the cross-sectional design from previous reports,
found that testing patterns differed significantly depending
on whether a patient had received PSA testing in the past.
Whereas the rates of PSA testing declined over time among
previously unscreened men, screening frequency remained
more constant among men with evidence of prior PSA testing.
In addition, although guidelines generally do not recommend
screening in men aged 70–75 years or older [3–6], there was

0.89
0.91
0.98

<0.0001
<0.0001
<0.0001

much less of a drop off in testing with age among men with
previous PSA screening. The findings suggest that once a man
is enrolled in a screening program, there is lower impact of
changes in external practice guidelines.
Our study also found that for men without previous screen-

1.00
1.00
0.98
Referent

0.96
0.97
0.96

0.88
0.90
0.92
Referent

0.84
0.87
0.90

1.04
1.03
1.00

0.9416
0.9720
0.0602

ing, an increase in PSA testing was associated with increased
comorbidity, and a decrease was associated with advancing
age. Although the comorbidity findings appear counterintuitive [25], it may reflect more frequent contact with health care

0.91
0.93
0.95

<0.0001
<0.0001
<0.0001

providers and hence a greater opportunity to order PSA testing. In addition, previous studies have documented aggressive treatment of low-risk prostate cancer among men with
significant comorbidity [26], suggesting that in contrast to

Family Medicine and Community Health 2017;5(2):109–118114
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Table 3. Multivariate analysis of prostate-specific antigen testing

Table 3 (continued)

among men with no prostate-specific antigen testing in the previous
2 years

Adjusted

95% Confidence

OR
Adjusted

95% Confidence

OR

physician density
1 (lowest)
2
3
4 (highest)
Urologist density
1 (lowest)
2
3
4 (highest)

115 

Lower

Upper

Referent
0.98
0.94
0.66

0.96
0.92
0.65

1.00
0.95
0.68

0.0240
<0.0001
<0.0001

Referent
1.04

1.01

1.06

0.0034

limits
Lower

Age group (years)
67–69
70–74
75–79
80+
Race
White
African American
Other
Comorbidity score
0
1
2
3+
Geographic region
Northeast
Midwest
South
West
Income quartile
1 (lowest)
2
3
4 (highest)
Education quartile
1 (lowest)
2
3
4 (highest)
Primary care

P

Upper

Referent
0.96
0.84
0.57

0.94
0.82
0.56

0.98
0.86
0.59

<0.0001
<0.0001
<0.0001

Referent
0.92
1.18

0.90
1.15

0.95
1.21

<0.0001
<0.0001

Calendar year
2009
2010
2011
2012
State buy-in
No
Yes

P

limits

OR, odds ratio.

age, clinicians may have difficulty assessing competing risks
Referent
1.53
1.46
1.40
Referent
0.88
1.51
1.05

of comorbid illnesses. We found that in both the previously
1.50
1.43
1.37

1.55
1.50
1.43

<0.0001
<0.0001
<0.0001

screened individuals and the unscreened individuals, the rate
of PSA testing was somewhat lower in African American
men compared with white men. Although the prostate cancer
incidence and mortality are higher in African Americans [1],

0.85
1.47
1.02

0.90
1.55
1.08

<0.0001
<0.0001
0.0014

0.80
0.80
0.85
Referent

0.78
0.78
0.83

0.83
0.82
0.87

<0.0001
<0.0001
<0.0001

0.88
0.91
0.95
Referent

0.86
0.89
0.93

0.91
0.94
0.97

<0.0001
<0.0001
<0.0001

screening guidelines that stratify recommendations by race [5]
differentiate only the age to start screening. Previous studies
in younger men [20, 22, 25] and Medicare patients [11] showed
either no racial disparity in PSA testing use [11, 20, 22] or only
a modest difference [25].
Prior studies used administrative data from Medicare
beneficiaries and the Department of Veterans Affairs as
well as population-based surveys to examine the use of PSA
testing according to patient characteristics, physician factors, geographic region, and changes in practice guidelines
[7–12]. Using a cross-sectional approach, these studies found
PSA rates of up to 40%–50% during a defined time period,
with only a modest decline with advancing age and comor-

0.79
0.85
0.97
Referent

0.75
0.81
0.94

1.02
0.93
0.90
Referent

0.97
0.89
0.88

0.83
0.89
0.99

<0.0001
<0.0001
0.0199

bidity. There was also significant variability in the rate of
PSA testing among primary care providers [11], and it was
more common in regions with greater total expenditures
and end-of-life care [12]. Following publication of the 2008

1.07
0.97
0.93

0.4534
0.0003
<0.0001

USPSTF guidelines recommending routine screening not
be performed in men older than 75 years, studies reported
a modest decline in screening rates [8, 11, 13]. In addition,
publication of clinical trial data was also associated with a
Family Medicine and Community Health 2017;5(2):109–118
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small decrease in the use of screening [9]. Previous studies

the study did not include men who were enrolled in Medicare

from single institutions also examined the potential impact

Advantage Plans or those not enrolled in Medicare Part B,

of the 2012 USPSTF guidelines on screening. These stud-

and it was not known if the trends of PSA testing use in these

ies documented a decline in the overall rate of PSA testing

groups would be similar. The study was also limited to an

among primary care providers [16] and in prostate biopsies

older patient population, and thus the impact of guidelines and

[15]. Three recently published articles used the National

other factors in younger, privately insured individuals could

Health Interview Survey to examine PSA testing receipt

not be measured. Moreover, despite the lack of USPSTF rec-

before and after the publication of the 2012 USPSTF guide-

ommendations, PSA testing has remained a covered benefit

lines. One study found that although there was a significant

under Medicare without any out-of-pocket expenses. Analyses

decline in testing in men older than 50 years, there contin-

in younger patient groups have found mixed results with

ued to be a high frequency of screening in men older than

regard to changes in PSA testing uptake after 2012 [20–22].

75 years and/or with significant comorbidity [20]. Another

Finally, because patient-level socioeconomic status was not

study found that screening frequency increased from 2005

available in claims data, we used small area measures, a com-

to 2008 but declined from 2010 to 2013, which correlated

monly used approach in studies of Medicare data.

with a decrease in early-stage cancer incidence [21]. A third

In summary, we found that receipt of PSA testing is highly

study found that the decrease in PSA testing from 2010 to

dependent on whether an individual was tested in the recent

2013 was limited only to men younger than 75 years [22].

past. Although overall rates of PSA testing use declined with

In contrast, an analysis of the 2012 Behavioral Risk Factor

time, the largest decrease occurred in both previously screened

Surveillance System data reported only a minimal decline in

and unscreened men in 2012, which may reflect publication of

PSA testing receipt, with an estimate of 37.1% receiving PSA

the most recent USPSTF guidelines.

testing among men aged 50 years or older [16]. Because of
differences in study design (cross-sectional vs. longitudinal)
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Significance statement

Our study design also could not measure patient and physi-

Universal screening for prostate cancer with prostate specific

cian preferences regarding screening, both of which were

antigen (PSA) testing in men has not been recommended by

likely associated with screening receipt. However, the results

the US Preventive Services Task Force since 2012 and had an

were clustered by provider, which accounts in part for phy-

indeterminate recommendation prior to that. However, previ-

sician practice patterns. Because of incomplete claims data,

ous studies that have shown changes following guidelines have
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not considered whether men were already undergoing screen-

11. Goodwin JS, Jaramillo E, Yang L, Kuo Y-F, Tan A. Is anyone

ing. Using a population-based sample of Medicare beneficiar-

listening? Variation in PSA screening among providers for men

ies, we found that among previously unscreened men, there was

75+ before and after United States Preventive Services Task

a significant decline in testing from 2009–2012 that was most

Force recommendations against it: a retrospective cohort study.

pronounced in 2012. In contrast for men already screened, the
decline was much less apparent. The findings suggest that receipt
of PSA, including after the 2012 guidelines, is highly dependent
on whether an individual was tested in the recent past.

PLoS One 2014;9:e107352.
12. Bynum J, Song Y, Fisher E. Variation in prostate-specific antigen
screening in men aged 80 and older in fee-for-service Medicare.
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